OPKO HEALTH, INC. annual report, FY2023

OPKO Health, Inc. — 2023 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 1, 2024. OPKO is a diversified healthcare company with diagnostics and pharmaceutical segments. Its principal businesses include BioReference laboratory services, Rayaldee, and pharmaceutical operations and development programs, including ModeX. Somatrogon (NGENLA) is commercialized by Pfizer under a collaboration.

Financial results and liquidity

Metric	2023	2022
Total revenue	$863.5 million	$1,004.2 million
Operating loss	$157.0 million	$226.3 million
Net loss	$188.9 million	$328.4 million
Loss per share, basic and diluted	$0.25	$0.46
Cash used in operating activities	$28.2 million	$95.2 million
Cash and cash equivalents at year-end	$95.9 million	$153.2 million

• Revenue comprised $515.3 million from services, $167.6 million from products, and $180.7 million from intellectual property and other, including collaboration and milestone revenue.
• Cost of revenue was $545.4 million; the resulting gross profit was approximately $318.1 million, or 36.8% of revenue. Operating margin was approximately negative 18.2%; net margin was approximately negative 21.9%.
• Diagnostics revenue fell 32% to $515.3 million, and the segment recorded a $155.6 million operating loss. Pharmaceuticals revenue rose 40% to $348.2 million, with $41.2 million of operating income. Corporate operating costs produced a $42.6 million loss.
• Rayaldee sales increased 14% to $31.0 million. Pharmaceutical product revenue rose 17%; intellectual-property and other revenue increased to $180.7 million, substantially reflecting Pfizer’s $90 million NGENLA U.S. approval milestone and Merck’s $50 million upfront payment.
• Research and development expense increased 21% to $89.6 million, primarily reflecting ModeX early-stage programs and a $12.5 million payment to Sanofi, partly offset by lower Somatrogon study costs. Selling, general and administrative expense declined 19% to $300.6 million.
• Interest expense was $13.5 million. Other expense, net, was $17.0 million, including a $23.0 million loss from the change in fair value of OPKO’s GeneDx Holdings investment. The income tax provision was $4.4 million.
• Total debt was $249.3 million at year-end, including $214.3 million of convertible notes and $25.3 million drawn on credit lines. The revolving facility had $12.7 million available under the broader liquidity disclosure; another credit-facility note reports $7.5 million available, so the filing’s available-borrowing figures are not consistent across sections.
• Current assets were $309.5 million and current liabilities were $200.1 million. OPKO reported total assets of $2.012 billion and shareholders’ equity of $1.389 billion.

Material changes versus the prior period

• Total revenue decreased 14%, mainly because service revenue fell with lower COVID-19 testing demand and reimbursement, as well as the absence of GeneDx revenue following its 2022 sale. In 2023, service revenue was down $240.4 million year over year.
• Operating loss narrowed by $69.2 million and net loss by $139.5 million. Net loss in 2022 included a $150.9 million fair-value loss on the GeneDx Holdings investment, compared with $23.0 million in 2023; 2022 also included a $63.5 million income tax benefit, versus a $4.4 million provision in 2023.
• Pharmaceutical operating results improved from a $13.0 million loss to $41.2 million of income, supported by milestone and collaboration revenue. Diagnostics remained loss-making despite lower costs and continued cost-reduction efforts.
• Cash declined by $57.3 million during 2023. Operating cash outflow improved from $95.2 million to $28.2 million; investing activities used $18.2 million and financing activities used $11.3 million.
• Quarterly results show fourth-quarter 2023 revenue of $181.9 million and net loss of $66.5 million, compared with fourth-quarter 2022 revenue of $185.3 million and net loss of $85.2 million.

Outlook, risks, contingencies and unusual items

• Management stated that year-end cash and available credit were expected to cover anticipated operating and debt-service needs beyond 12 months, but noted that estimates depend on assumptions and that OPKO has not historically generated sustained positive cash flow. The filing gives no specific revenue or earnings guidance.
• Management reported progressive Rayaldee sales growth during 2023; fourth-quarter prescriptions rose approximately 13.6% year over year. Commercial and Medicare Part D payer contracts covered 63% and 71% of relevant U.S. covered lives, respectively. Management also noted continuing work to broaden coverage.
• BioReference faces the challenge of replacing COVID-19 testing revenue with growth in its core testing business. OPKO cites payer reimbursement pressure, billing and collection complexity, testing-volume risk, and the need for further cost management.
• In January 2024, after year-end, OPKO issued $230 million of 3.75% convertible notes due 2029 for approximately $222 million net proceeds. It used $146.3 million to repurchase approximately $144.4 million principal amount of 2025 notes and approximately $50 million to repurchase common shares. Separately, it exchanged $55 million of affiliate-held 2023 notes plus accrued interest for approximately $71.1 million principal amount of 2029 affiliate notes. These post-year-end transactions materially changed the capital structure.
• ModeX’s BARDA contract provides an initial $59 million over five years, subject to performance, with up to $109.6 million of additional milestone funding. The government may terminate the contract; OPKO reported $57.8 million of remaining transaction price at year-end, excluding unexercised options.
• OPKO is appealing an Israel Tax Authority assessment of approximately $246 million, including interest. The filing reports a $9.9 million accrual related to uncertain tax positions; it provides no assurance on the assessment’s outcome. BioReference also faces a Texas Medicaid inquiry concerning claims dating from 2005, with potential liability not yet determinable.
• BioReference is subject to a five-year Corporate Integrity Agreement following a 2022 settlement. OPKO and BioReference agreed to pay $10 million plus interest and admitted to certain above-market physician office-space rental payments and failure to return related overpayments; they denied other allegations. Failure to comply with the agreement could result in penalties or exclusion from federal healthcare programs.
• OPKO reported goodwill of $598.3 million and net intangible assets of $740.3 million, in addition to $195.0 million of in-process research and development. Management warned that weaker-than-assumed performance in diagnostics or the Ireland reporting unit could result in material impairment charges; no impairment was recorded for 2023.
• The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The audit’s critical audit matter was the estimation of variable consideration in service revenue. OPKO stated that it had no material cybersecurity incidents affecting the company.

Important facts for investors to verify

• Whether BioReference’s core testing volumes, reimbursement, margins, and cash generation recover sufficiently to offset declining COVID-19 testing revenue.
• How much of 2023 pharmaceutical revenue and operating improvement reflects recurring product sales versus upfront payments and milestones, and the timing and likelihood of future collaboration payments.
• The final impact of the January 2024 convertible-note issuance, debt repurchases, share buyback, conversion terms, and related-party note exchange on liquidity, interest costs, and potential dilution.
• The status and potential financial exposure of the Israel tax assessment, Texas Medicaid inquiry, payor audits, and Corporate Integrity Agreement obligations.
• Whether cash, borrowing availability, and covenant compliance remain adequate; clarify the differing credit-facility availability figures disclosed in the filing.
• Whether actual results support the carrying values of goodwill, intangible assets, and the remaining GeneDx Holdings investment, and whether any further impairments arise.